IL33 and endometriosis: IL-33 perpetuates inflammation, angiogenesis, and lesion proliferation in endometriosis [38] and promotes the invasiveness of HESCs through the ST2/MAPK/MMP-9 pathway activated by 17β-estradiol [57].